Fortress Biotech, Inc.
corporate_fare Company Profile
Fortress Biotech, Inc. (NASDAQ:FBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for FBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for FBIO spans 4, 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Fortress CEO/Chairman Rosenwald Buys 136,723 Shares for $252,583
- Fortress 10-Q: Q3 Revenue $19.2M, $7.9M Net Loss, $152.2M Cash and No Parent Debt
- Fortress Biotech Q2 Revenue Up 14% to $18.7M; Cash Position Strengthens to $196.6M
- Q1 Net Income Soars to $108.4M Driven by $205M PRV Sale, Boosting Cash and Reducing Debt
- Fortress Biotech Reports Q1 Net Income Exceeding Market Cap Driven by PRV Sale
Financial Snapshot
Short Interest & Short Volume
23.59 days to coverFINRA reported short interest of 4,611,017 shares in FBIO as of the October 30, 2026 settlement, a 2.0% increase from the prior period — about 23.6 days to cover at its recent average daily volume. On November 20, 2026, 57.6% of FBIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.